Ultragenyx Pharmaceutical (RARE)

• Market cap: $2.84B
• 1 day: 0.82%
• 5 days: 1.69%
• 1 month: 6.88%
• 3 months: -15.88%
• 6 months: -29.10%
• Year to date: -28.29%
• 1 year: -48.27%
• 5 years: -64.69%
• 10 years: -72.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Employees: 1,294

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

84% more call options, than puts

Call options by funds: $130M | Put options by funds: $70.9M

29% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 42

6% more capital invested

Capital invested by funds: $3.22B [Q1] → $3.41B (+$188M) [Q2]

3.06% more ownership

Funds ownership: 96.05% [Q1] → 99.1% (+3.06%) [Q2]

2% more funds holding

Funds holding: 297 [Q1] → 304 (+7) [Q2]

7% more repeat investments, than reductions

Existing positions increased: 114 | Existing positions reduced: 107

14% less funds holding in top 10

Funds holding in top 10: 7 [Q1] → 6 (-1) [Q2]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $34 15% upside
• Avg. target: $75 152% upside
• High target: $128 334% upside

8 analyst ratings

• positive: 7 88%
• neutral: 1 13%
• negative: 0 0%

Canaccord Genuity Whitney Ijem	334% upside $128	Buy Maintained	8 Aug 2025
Cantor Fitzgerald Kristen Kluska	256% upside $105	Overweight Maintained	6 Aug 2025
HC Wainwright & Co. Raghuram Selvaraju	171% upside $80	Buy Assumed	28 Jul 2025
Wedbush Laura Chico	15% upside $34	Neutral Maintained	14 Jul 2025
Morgan Stanley Jeffrey Hung	86% upside $55	Overweight Maintained	14 Jul 2025